Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2010-06-24
2011-11-29
Spector, Lorraine (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S138100, C530S387100, C530S388220, C530S388800, C530S350000, C530S388850
Reexamination Certificate
active
08067001
ABSTRACT:
An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
REFERENCES:
patent: 6072047 (2000-06-01), Rauch et al.
patent: 6252050 (2001-06-01), Ashkenazi et al.
patent: 6294546 (2001-09-01), Rosen et al.
patent: 6313269 (2001-11-01), Deen et al.
patent: 6342363 (2002-01-01), Ni et al.
patent: 6342369 (2002-01-01), Ashkenazi
patent: 6433147 (2002-08-01), Ni et al.
patent: 6461823 (2002-10-01), Ni et al.
patent: 6534061 (2003-03-01), Goddard et al.
patent: 6635482 (2003-10-01), Yu et al.
patent: 6872568 (2005-03-01), Ni et al.
patent: 6965023 (2005-11-01), Reed et al.
patent: 7105640 (2006-09-01), Desnoyers et al.
patent: 7279160 (2007-10-01), Zhou et al.
patent: 7476383 (2009-01-01), Zhou et al.
patent: 7704502 (2010-04-01), Zhou et al.
patent: 2002/0072091 (2002-06-01), Ni et al.
patent: 2002/0098550 (2002-07-01), Ni et al.
patent: 2003/0228309 (2003-12-01), Salcedo et al.
patent: 0125023 (1984-11-01), None
patent: WO9907861 (1990-07-01), None
patent: WO9832856 (1998-07-01), None
patent: WO9835986 (1998-08-01), None
patent: WO9841629 (1998-09-01), None
patent: WO9846643 (1998-10-01), None
patent: WO9851793 (1998-11-01), None
patent: WO9902653 (1999-01-01), None
patent: WO9903992 (1999-01-01), None
patent: WO9909165 (1999-02-01), None
patent: WO9911791 (1999-03-01), None
patent: WO9912963 (1999-03-01), None
patent: WO9937684 (1999-07-01), None
patent: WO0066156 (2000-11-01), None
patent: WO0067793 (2000-11-01), None
patent: WO0073349 (2000-12-01), None
patent: WO0075191 (2000-12-01), None
patent: WO0119861 (2001-03-01), None
patent: WO0177342 (2001-10-01), None
patent: WO0183560 (2001-11-01), None
patent: WO02079377 (2002-10-01), None
Mayer et al., Mitochondrial regulation of apoptosis, News Physiol. Sci. 18: 89-94, 2003.
Ostrow et al., “Determination of complimentary therapy use in HIV-infected individuals receiving antiretroviral or anti-opportunistic agents,” J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 15(2):115-20 (1997).
Pan et al., “The receptor for the cytotoxic ligand TRAIL,” Science 276(5309):111-3 (1997).
Pan et al., “An antagonist decoy receptor and a death domain-containing receptor for TRAIL,” Science 277 (5327):815-8 (1997).
Reichel et al., “Radiological changes in the cervical spine in rheumatoid arthritis-prognostic factors obtained by a cross-sectional study,” Z. Rheumatol. 61(6):710-7 (2000).
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. USA 79:1979-83 (1982).
Schneider et al., “TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kB,” Immunity 7(6):831-6 (1997).
Seitz et al., “Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different American college of rheumatology response groups to methotrexate,” Rhemuatol. 30(1):28-35 (2003).
Sheridan et al., “Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors,” Science 277 (5327):818-21 (1997).
Silvestris et al., “Recent advances in understanding the pathogenesis of anemia in multiple myeloma” Int. J. Hematol. 78(2):121-5 (2003).
Solomon et al., “Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice,” Arthritis Rheum. 46(12):3136-42 (2002).
Song et al., “Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression,” 191(7):1095-1103 (2000).
Sprick et al., “FADD/MORTI and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2,” Immunity 12:599-609 (2000).
Srivastava, “TRAIL/Apo-2L:Mechanism and clinical applications in cancer,” Neoplasia 3(6):535-46 (2001).
Steiner et al., “Novel autoantibodies for the diagnosis of rheumatoid arthritis,” Z. Rheumatol. 61(6):667-73 (2002).
Stites et al., eds. Basic and Clinical Immunology, 8th Ed., (Appleton & Lange:Norwalk, CT), p. 137 (1994).
Straughn et al., “Anti-tumor activity ofTRA-8 anti-death receptor 5 (DRS) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model,” Gynecol. Oncology 101(1):46-54 (2006).
Sun et al., “Specific cytotoxicity and immuno-regulation by EBV-specific CD4+ T cells,” 42nd Abstract of Ann. Meet. Amer. Canc. Soc. Hematol., The Moscone Center, San Fran., CA Dec. 1-5, 2000.
Vane, “Aspirin and other anti-inflammatory drugs,” Thorax 55(Suppl. 5):S3-S9 (2000).
Wajant et al., “Dominant-negative FADD inhibits TNFR60-, Fas/Apol-, and TRAIL-R/Apo2-mediated cell death but not gene induction,” Curr. Biol. 8:113-6 (1998).
Walczak et al., “TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL,” EMBO 16(17):5386-97 (1997).
Walczak et al., “Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo,” Nat. Med. 5:157-63 (1999).
Wiley et al., “Identification and characterization of a new member of the TNF family that induces apoptosis,” Immunity 3(6):673-82 (1995).
Winter and Harris, “Humanized antibodies,” Immunology Today 14(6):243-246 (1993).
Yamada et al., “TRAIL causes cleavage of bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells,” Biochem. Biophys. Res. Commun. 265:130-3 (1999).
Zamai et al., “Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells,” J. Exp. Med. 188(12):2375-80 (1998).
Zhang et al., “Rising level of serum sTRAIL and its recipient DR4 in patients with lupus-nephritis,” Disi. Junyi. Daxue Xuebao. 24(11):1040-1 (2003).
Zhou et al., “Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody in prostate cancer,” Internat. J. Radiation Oncol. Biol. Phys. 54(2 Suppl.):224 (2002).
Adams et al., “Structural and funcational analysis of the interaction between agonist monoclonal antibody Apomab and the proapoptotic receptor DR5,” Cell Death Diff. 15:751-61 (2008).
Lamminmaki et al., “Crystal structure of a recombinant anti-estradiol Fab fragment in complex with 17 Beta-estradiol,” J. Biol. Chem. 276:36687-94 (2001).
MacCallum et al., “Antibody-antigen interactions: contact analysis and binding site topology,” J. Mol. Biol. 262:732-45 (1996).
Arai et al., “Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas,” Cancer Letters 13392):197-204 (1998).
Ashkenzai et al., “Safety and antitumor activity of recombinant soluble Apo2 ligand,” J. Clin. Invest. 104:155-62 (1999).
Bendele et al., “Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats,” Clin. Exp. Rheumatol. 17(5):553-60 (1999).
Berckmans et al., “Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism,” Arthritis Rheum. 46(11):2857-66 (2002).
Bodmer et al., “TRAIL receptor-2 signals apoptosis through FADD and caspase-8,” Nat. Cell Biol. 2:241-3 (2000).
Bonavida et al., “Selectivity of TRAIL-mediated a
Ichikawa Kimishisa
Kimberly Robert P.
Koopman William J.
Zhou Tong
Kaufman Claire
McKeon Meunier Carlin Curfman
Spector Lorraine
The UAB Research Foundation
LandOfFree
Antibody selective for a tumor necrosis factor-related... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody selective for a tumor necrosis factor-related..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody selective for a tumor necrosis factor-related... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4261445